Results 91 to 100 of about 5,953 (226)

Developing a community HCV service: project ITTREAT (Integrated Community based Test - stage - TREAT) service for people who inject drugs [PDF]

, 2017
Liver disease is now the third most common cause of premature death in the UK, with chronic viral hepatitis being an important contributory factor.
Hashim, Ahmed, O'Sullivan, Margaret, Verma, Sumita, Williams, Hugh   +3 more
core   +1 more source

Non‐Specialist Physicians Successfully Treat Hepatitis C Infection With Simplified Care Pathway in France

Journal of Viral Hepatitis, Volume 32, Issue 8, August 2025.
ABSTRACT To eliminate hepatitis C virus (HCV) infection in France, prescribing rights for sofosbuvir/velpatasvir (SOF/VEL) were extended to non‐specialists, and a simplified care pathway for non‐severe patients was implemented. Patients can thus be treated once diagnosis is confirmed (“Test and Treat” model).
Denis Ouzan, Laurent Cattan, Vincent Leroy, Jean Pierre Bronowicki, Alexandra Heurgué, Dan Pospait, Ghassan Riachi, Christophe Renou, Michel Antoni, Laure Ekrief, Laurent Cuissard, Magdalena Meszaros, Jean‐Jacques Meurisse, Laurent Roudiere, Thierry Constant, Kouadjo Joseph Koffi, Hatem Salloum, Juliette Foucher, Philippe Gouiry, Malek Bentayeb, Laura E. Telep, Teri Chew, Nicolas J.‐P. Martin, Stanislas Pol, on behalf of the HELIOS study group, Pajaud Passe‐Coutrin   +25 more
wiley   +1 more source

The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

Український Журнал Нефрології та Діалізу, 2020
Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to ...
M. Mostafi, M. Jabin, Z. Chowdhury, M.U. Khondoker, S.M. Ali, R. Tamanna, R. Rezwan, S.B. Alomgir   +7 more
doaj   +1 more source

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection [PDF]

The Korean Journal of Internal Medicine, 2023
Hyun Phil Shin
doaj   +1 more source

Characterization of resistance associated variants associated to NS5A inhibitors in patients with chronic hepatitis C [PDF]

, 2017
Traballo fin de grao (UDC.CIE). Bioloxía. Curso 2016/2017[Resumen] La presencia de variantes asociadas a resistencia (VAR) en la región NS5A puede comprometer la eficacia de los antivirales de acción directa (AADs).
Gomollón Guevara, Verónica Alejandra
core  

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review [PDF]

, 2017
Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S.
Falade-Nwulia, Oluwaseun, Fried, Michael W., Nelson, David R., Segal, Jodi B., Suarez-Cuervo, Catalina, Sulkowski, Mark S.   +5 more
core   +2 more sources

Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19 [PDF]

, 2020
Vishal Mevada, Pravin Dudhagara, Himani Gandhi, Nilam Vaghamshi, Urvisha Beladiya, Rajesh Patel   +5 more
openalex   +1 more source

Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection [PDF]

, 2021
Rowan Ahmed, Roaa Kareem, Nanditha Venkatesan, Rinky A Botleroo, Opemipo D Ogeyingbo, Renu Bhandari, Mallika Gyawali, Abeer O Elshaikh   +7 more
openalex   +1 more source

Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023

, 2023
A total of 105,024 individuals have initiated direct acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection in Australia, including 100,684 individuals through Pharmaceutical Benefits Scheme (PBS) during 2016 to 2022, and an ...
Carson, Joanne , Dore, Gregory , Hajarizadeh, Behzad   +2 more
core   +1 more source

EXPERIENCE IN THE TREATMENT OF HEPATITIS C IN PREGNANT PATIENTS AT THE HEPATITIS CLINIC OF THE VERACRUZ HIGH SPECIALTY HOSPITAL

Annals of Hepatology
Introduction and Objectives: Currently, HCV treatment options during pregnancy are not well-defined. Typical clinical practice is to refer and link pregnant women for treatment after pregnancy and breastfeeding; however, in practice, very few have ...
Maria Teresa Guzmán Terrones, Eve Flynn Ferreira, Luis Del Carpio Orantes, Raúl Terrones Castro   +3 more
doaj   +1 more source